Fate Therapeutics Announces Promising Data from Phase Ib Study of ProHemaFate Therapeutics, Inc. announced promising clinical results from a Phase Ib trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy. [Press release from Fate Therapeutics, Inc. discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release

Study Points to Novel Way to Improve Outcomes from Umbilical Cord Blood TransplantsA new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient’s body than with a conventional cord blood transplant procedure. [Press release from the Perelman School of Medicine at the University of Pennsylvania discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release